151 related articles for article (PubMed ID: 22404973)
1. Development of five new melanoma low passage cell lines representing the clinical and genetic profile of their tumors of origin.
de Miera EV; Friedman EB; Greenwald HS; Perle MA; Osman I
Pigment Cell Melanoma Res; 2012 May; 25(3):395-7. PubMed ID: 22404973
[No Abstract] [Full Text] [Related]
2. A case of unknown primary melanoma detected with a BRAF gene mutation from a pleural fluid cell block.
Yamamoto S; Kuriyama H; Kashiwada-Nakamura K; Kajihara I; Makino K; Aoi J; Miyashita A; Yoshida C; Kubo Y; Fukushima S
J Dermatol; 2023 Sep; 50(9):e305-e306. PubMed ID: 37088959
[No Abstract] [Full Text] [Related]
3. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
Br J Cancer; 2011 Jul; 105(2):327-8. PubMed ID: 21694724
[No Abstract] [Full Text] [Related]
4. Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
Baiter M; Schuler G; Hartmann A; Schneider-Stock R; Heinzerling L
Dermatology; 2015; 231(2):127-33. PubMed ID: 26138035
[TBL] [Abstract][Full Text] [Related]
5. Cells to Surgery Quiz: October 2015.
Aldahan AS; Mlacker S; Shah VV; Samarkandy S; Alsaidan M; Nouri K
J Invest Dermatol; 2015 Oct; 135(10):e18. PubMed ID: 26358388
[No Abstract] [Full Text] [Related]
6. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
7. Comparative genomic characterization of melanoma of known and unknown primary.
Rassy E; Boussios S; Chebly A; Farra C; Kattan J; Pavlidis N
Clin Transl Oncol; 2021 Nov; 23(11):2302-2308. PubMed ID: 33934271
[TBL] [Abstract][Full Text] [Related]
8. Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.
Staaf J; Harbst K; Lauss M; Ringnér M; Måsbäck A; Howlin J; Jirström K; Harland M; Zebary A; Palmer JM; Ingvar C; Olsson H; Newton-Bishop J; Hansson J; Hayward N; Gruis N; Jönsson G
J Invest Dermatol; 2014 Dec; 134(12):3000-3003. PubMed ID: 24999598
[No Abstract] [Full Text] [Related]
9. B-RAF and melanocytic neoplasia.
Gill M; Celebi JT
J Am Acad Dermatol; 2005 Jul; 53(1):108-14. PubMed ID: 15965430
[TBL] [Abstract][Full Text] [Related]
10. RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma.
Goedert L; Pereira CG; Roszik J; Plaça JR; Cardoso C; Chen G; Deng W; Yennu-Nanda VG; Silva WA; Davies MA; Espreafico EM
Oncotarget; 2016 Jun; 7(24):36711-36718. PubMed ID: 27167340
[TBL] [Abstract][Full Text] [Related]
11. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.
Rabbie R; Ferguson P; Molina-Aguilar C; Adams DJ; Robles-Espinoza CD
J Pathol; 2019 Apr; 247(5):539-551. PubMed ID: 30511391
[TBL] [Abstract][Full Text] [Related]
12. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
Platz A; Egyhazi S; Ringborg U; Hansson J
Mol Oncol; 2008 Apr; 1(4):395-405. PubMed ID: 19383313
[TBL] [Abstract][Full Text] [Related]
13. Collision of chronic lymphocytic leukemia/small lymphocytic lymphoma and melanoma.
Dueber JC; Coffin CM
Blood; 2013 Jun; 121(24):4819. PubMed ID: 23923507
[No Abstract] [Full Text] [Related]
14. Balloon cell melanoma possessed the ability to develop BRAF V600E mutation in cancer cells.
Chen YY; Lan CE; Yen MC; Cheng ST
Kaohsiung J Med Sci; 2021 Feb; 37(2):154-155. PubMed ID: 33118306
[No Abstract] [Full Text] [Related]
15. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
[No Abstract] [Full Text] [Related]
16. Molecular characterization of novel melanoma cell lines.
Zanna P; Maida I; Turpin Sevilla MC; Susca FC; Filotico R; Arciuli M; Cassano N; Vena GA; Cicero R; Guida G
J Biol Regul Homeost Agents; 2011; 25(2):239-47. PubMed ID: 21880213
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Profiling in Cutaneous Melanoma: Caveats for Clinicians.
Sominidi-Damodaran S; Pittelkow MR; Meves A
Mayo Clin Proc; 2016 Aug; 91(8):1147-8. PubMed ID: 27492918
[No Abstract] [Full Text] [Related]
18. Characterization of a new human melanoma cell line with CD133 expression.
Gil-Benso R; Monteagudo C; Cerdá-Nicolás M; Callaghan RC; Pinto S; Martínez-Romero A; Pellín-Carcelén A; San-Miguel T; Cigudosa JC; López-Ginés C
Hum Cell; 2012 Jun; 25(2):61-7. PubMed ID: 22529031
[TBL] [Abstract][Full Text] [Related]
19. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
20. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.
Dutton-Regester K; Kakavand H; Aoude LG; Stark MS; Gartside MG; Johansson P; O'Connor L; Lanagan C; Tembe V; Pupo GM; Haydu LE; Schmidt CW; Mann GJ; Thompson JF; Scolyer RA; Hayward NK
Pigment Cell Melanoma Res; 2013 Nov; 26(6):852-60. PubMed ID: 23890154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
